Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
MWN-AI** Summary
Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneer in precision nerve-targeted treatments, has announced that its abstract on long-term pain mitigation in pancreatic adenocarcinoma has been selected as a Featured Abstract for a podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting. The event will take place from April 11-15, 2026, in Toronto, Canada. The study, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” evaluates the effectiveness of transvascular radiofrequency (RF) energy-based ablation in achieving sustained pain relief for patients afflicted with this aggressive cancer.
The presentation, which highlights critical advancements in managing cancer-related pain, will be given by Dr. Lindsay Machan on April 12. Brad Hauser, CEO of Autonomix, expressed enthusiasm over the selection, emphasizing the significance of novel approaches to alleviate severe pain associated with pancreatic adenocarcinoma, a condition often characterized by debilitating and hard-to-manage symptoms.
Autonomix Medical is committed to revolutionizing treatment methodologies through its proprietary technology designed to target nerve activity via a minimally invasive, catheter-based system. This innovative platform holds promise for not only pancreatic cancer but also a wider spectrum of indications, including chronic pain management and cardiovascular diseases.
The Society of Interventional Radiology Annual Scientific Meeting serves as a distinguished platform for sharing pivotal research and advancements in minimally invasive, image-guided therapies, positioning Autonomix at the forefront of cutting-edge medical innovation. The company’s investigational technology remains in the trial phase and is not yet available in the U.S. market. For further information, Autonomix encourages interested parties to visit their website and connect via various social media platforms.
MWN-AI** Analysis
Autonomix Medical, Inc. (NASDAQ: AMIX) recently announced its selection for a Featured Abstract and podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting. The focus of this presentation is on their innovative approach to long-term pain mitigation in patients suffering from pancreatic adenocarcinoma, an area of significant clinical need.
The recognition by SIR highlights the clinical significance of Autonomix's research on transvascular RF energy-based ablation. By addressing pain management in pancreatic cancer, a condition known for causing severe discomfort and diminished quality of life, Autonomix taps into a critical unmet need. Investors should note that the medical community's reception at such a prestigious event could positively influence the company's visibility and credibility.
From an investment perspective, Autonomix's innovative technology may appeal to institutional investors looking for high-growth opportunities in the healthcare sector. The potential to revolutionize pain management methodologies positions Autonomix favorably, particularly as global healthcare demands for effective cancer treatments continue to rise. However, it’s essential to approach this stock with a balanced view. While advancements and recognition can drive stock performance, investors should remain cognizant of the risks associated with research-stage companies, particularly the uncertainty surrounding regulatory approvals and market entry.
Moreover, Autonomix's emphasis on versatile applications for its proprietary technology beyond pancreatic cancer presents a broader potential revenue stream, enhancing its long-term investment attractiveness. As the company progresses through clinical trials, the outcomes will be crucial for further validating its technology and influencing market sentiment.
In conclusion, Autonomix's recognition at SIR 2026 marks an important milestone. Investors might consider accumulating shares, keeping an eye on upcoming trial results and regulatory developments, while being mindful of inherent risks in biotech investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its abstract titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been selected as a Featured Abstract for podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada.
The abstract is among a select group recognized for its scientific merit and clinical significance and will also be highlighted in the Journal of Vascular and Interventional Radiology (JVIR) 2026 Annual Scientific Meeting Supplement.
The presentation will be delivered by Dr. Lindsay Machan on Saturday, April 12, from 4:03 PM to 4:12 PM.
The study evaluates long-term outcomes of denervation using transvascular radiofrequency (RF) energy-based ablation in patients with pancreatic adenocarcinoma, focusing on sustained pain mitigation, an area of critical unmet need for patients suffering from this aggressive disease.
“Being selected for a Featured Abstract presentation at SIR underscores the importance of advancing novel approaches to address cancer-related pain,” said Brad Hauser, CEO of Autonomix. “We are encouraged by the growing body of evidence supporting our technology and look forward to sharing these important findings with the interventional radiology community.”
Pancreatic adenocarcinoma is often associated with severe, difficult-to-manage pain that significantly impacts quality of life. Autonomix Medical’s proprietary technology aims to target and modulate nerve activity through a minimally invasive, transvascular approach, potentially offering a new therapeutic option for pain management.
The Society of Interventional Radiology Annual Scientific Meeting is a premier global event bringing together physicians, researchers, and industry leaders to share cutting-edge research and advancements in minimally invasive, image-guided therapies. For more information, please visit the conference website.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ**
How might Autonomix Medical Inc. AMIX's featured abstract at the SIR 2026 meeting influence investor sentiment regarding its transvascular RF energy-based ablation technology for pancreatic cancer pain management?
Given the focus of Autonomix Medical Inc. AMIX on innovative nerve-targeted treatments, what are the potential market implications if their technology gains FDA approval for pancreatic adenocarcinoma?
What competitive advantages does Autonomix Medical Inc. AMIX's proprietary catheter-based microchip sensing array offer compared to existing pain management solutions for patients with pancreatic cancer?
How will the recognition of Autonomix Medical Inc. AMIX’s research at a prominent conference impact its reputation and partnerships within the medical device industry, potentially affecting future funding?
**MWN-AI FAQ is based on asking OpenAI questions about Autonomix Medical Inc. (NASDAQ: AMIX).
NASDAQ: AMIX
AMIX Trading
-0.61% G/L:
$0.3891 Last:
35,634 Volume:
$0.3945 Open:
